Gavi, the Vaccine Alliance, and the Bavarian Nordic laboratory that produces the MPOX vaccine, signed an agreement on Wednesday, September 18, guaranteeing the supply of 500,000 doses of serum to African countries affected by the epidemic in 2024.
The MVA-BN vaccine “It received WHO prequalification on 13 September and the Bavarian Nordic countries will be ready to supply the vaccines pending the signing of a supply agreement with Unicef. [l’agence de l’ONU pour l’enfance]partner of the Gavi alliance, which will deliver these doses »evokes a joint press release.
Meanwhile, the Global Fund, a global public-private partnership that fights, among other things, AIDS, tuberculosis and malaria, announced the payment of 9.5 million dollars (about 8.5 million euros) to the Democratic Republic of the Congo (DRC), considered the epicentre of the current mox epidemic.
These funds should help the authorities of the Democratic Republic of Congo to carry out their “emergency response” in the worst-affected areas of the country. The Democratic Republic of Congo had nearly 22,000 cases by the end of August and more than 700 deaths recorded since January, according to local authorities.
Meanwhile, mpox was present in 14 countries by late August, including Burundi, Congo-Brazzaville and the Central African Republic, according to the Africa CDC, the African Centre for Disease Control.
